Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g. NEAR(recruit, professionals, 20)).
Finds documents with the search term in word versions or composites. The asterisk * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g. lightweight*, *lightweight, *lightweight*).
A case of fulminant type 1 diabetes in a woman on tislelizumab for lung adenocarcinoma highlights the need for proactive monitoring of fasting glucose, HbA1c, and islet function in people given an immune checkpoint inhibitor.
Three trials point to the potential of fecal microbiota transplantation to enhance the efficacy of immune checkpoint inhibitor-based therapy in people with cancer.
Recent trials have shown survival benefits of intensified regimens in EGFR-mutant NSCLC, but they come at the cost of increased toxicity and treatment burden. So which patients should receive upfront intensification?
Familiarize yourself with the current evidence on risk factors, molecular pathology, and treatment strategies for lung cancer in nonsmoking women, and understand the critical role of gender susceptibility.
A complicated case in which a patient admitted with polyuria and polydipsia was diagnosed with arginine vasopressin deficiency, which was ultimately found to be a manifestation of lung cancer.
Do you want to assess your biomarker testing skills and management decisions? Use these simulation-based case studies based on realistic NSCLC scenarios to do so in a practical and secure environment.
In this interactive webinar, experts Dr. Subbiah, Dr. Drilon, and Dr. Williams discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.
This content is intended only for US-based healthcare providers.
A case of fulminant type 1 diabetes in a woman on tislelizumab for lung adenocarcinoma highlights the need for proactive monitoring of fasting glucose, HbA1c, and islet function in people given an immune checkpoint inhibitor.
A complicated case in which a patient admitted with polyuria and polydipsia was diagnosed with arginine vasopressin deficiency, which was ultimately found to be a manifestation of lung cancer.
An extremely rare case of combined small-cell lung cancer with adenocarcinoma. Such variants can be difficult to diagnose and treat. How would you manage this patient?
The ADAURA trial has, as of this year, demonstrated an overall survival benefit with the adjuvant use of osimertinib in people with resectable NSCLC.
We take an in-depth look at the study with Dr. Luis Paz-Ares, who outlines the study findings, discusses the clinical implications, and addresses the pertinent questions raised by the trial.
Lung cancer is the leading cause of cancer death in the United States (US) and globally [ 1 – 3 ]. Many risk factors for lung cancer have been identified, with cigarette smoking being the predominant cause [ 4 , 5 ]. Cigarette smoking causes 85–90% …
Thymic epithelial tumors (TETs) sit at a unique intersection of cancer, central tolerance, and autoimmunity. These tumors arise in the thymus, an immune-rich organ responsible for T-cell education, and despite their low tumor mutational burden …
This article provides a focused narrative review of salvage surgery after epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for non-small cell lung cancer (NSCLC). It highlights its conceptual differences from salvage …
Lung cancer is the most prevalent cancer and cause of death; most patients present themselves at an advanced stage and continuously acquire resistance to targeted agents, antibody–drug conjugates, chemotherapy, and immune checkpoint inhibitors. In …
In this interactive webinar, experts discuss best pathological practices within NSCLC and thyroid cancer, as well as how genomic testing can improve outcomes in clinical practice, using patient case studies as illustrations.
This content is intended only for US-based healthcare providers.
Expert-led, multiformat program which addresses the individualized management of NSCLC, through education on the detection of NTRK gene fusions, current evidence-based guidelines, and new and emerging therapies. Use the guidance on integrating shared decision making into clinical practice, drawing on insights from a patient on how best to communicate.
Non-small cell lung cancer (NSCLC), accounting for 85% of all lung cancer cases, continues to pose a severe global health challenge [ 1 ]. According to the 2022 Global Cancer Statistics [ 2 ], lung cancer remains the leading cause of cancer …
While anti-programmed death-1 (anti-PD-1) therapy has revolutionized lung cancer treatment, its efficacy remains limited by an immunosuppressive tumor microenvironment (TME). We therefore investigated whether combining anti-PD-1 inhibitor with …
Various therapeutic approaches have been developed for lung cancer, including chemotherapy, radiation therapy, and immune checkpoint inhibitors. However, these approaches, including chimeric antigen receptor (CAR)-T cell therapy, have shown …
Thymic epithelial tumors (TET), including thymomas and thymic carcinomas, are rare tumors, and for recurrent or metastatic TET, systemic treatment options are limited [ 1 ]. Immune checkpoint inhibitors (ICI) have progressively emerged as a key …
From the mechanistic contributions of pathogenic bacteria to tumor initiation, to the role dysbiosis plays in influencing systemic cancer behavior, understand the impact bacteria has as a driver of cancer development.